// App-Quantinova.ai

2020 : Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.

Researchers

Presenter

  • Olivier L. Chinot

Principal Investigators

  • Sylvie Romain

  • Cedric Revil

  • Timothy Cloughesy

  • Warren P. Mason

  • Ryo Nishikawa

  • Roger Henriksson

  • Frank Saran

  • Antoine F. Carpentier

  • Khe Hoang-Xuan

  • Petr Kavan

  • Dana Cernea

  • Alba Ariela Brandes

  • Yannick Kerloeguen

  • Christoph Mancao

  • L'Houcine Ouafik

  • Lauren E. Abrey

  • Wolfgang Wick

  • Emeline Tabouret

Medical Centers

  • Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • University of Southern California, Los Angeles, CA

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Saitama Medical University, Saitama, Japan

  • Regional Cancer Center Stockholm and Umea University, Stockholm/Umea, Sweden

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Assistance Publique-Hopitaux de Paris, Paris 13 University, Hopital Avicenne, Bobigny, France

  • APHP, UPMC, CRICM, Department of Neurology Mazarin, CHU Pitie-Salpetriere, Paris, France

  • Montreal University, Montreal, QC, Canada

  • Cancer Institute "Prof. Dr Ion Chiricuta", Cluj-Napoca, Romania

  • Azienda USL Bellaria-Maggiore Hospital, Bologna, Italy

  • University of Heidelberg Medical Center, Heidelberg, Germany

Locations

  • Canada

  • Romania

  • Japan

  • Italy

  • Germany

  • Switzerland

  • United Kingdom

  • United States

  • France

  • Sweden

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00943826

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved